Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression

Cancer Research

Volumn 56, Issue 15, 1996, Pages 3499-3507

  Dean, Nicholas ^a   McKay, Robert ^a   Miraglia, Loren ^a   Howard, Randy ^a   Cooper, Scott ^a   Giddings, June ^b   Nicklin, Paul ^b   Meister, Lothar ^c   Ziel, Ralf ^c   Geiger, Thomas ^c   Muller, Marcel ^c   Fabbro, Doriano ^c  

^a ISIS PHARMACEUTICALS   (United States)

^b Ciba Pharmaceuticals   (United Kingdom)

^c CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ISIS 3521; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL DIVISION; ENZYME INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; THIONUCLEOTIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 8944231156     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (Washington DC), 258: 607-614, 1992.
2. Asaoka, Y., Nakamura, S., Yoshida, K., and Nishizuka, Y. Protein kinase C, calcium and phospholipid degradation. Trends Biochem. Sci., 17: 414-417, 1992.
3. Dekker, L. V., and Parker, P. J. Protein kinase C - a question of specificity. Trends Biochem. Sci., 19: 73-77, 1994.
4. Yuspa, S. H. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis, thirty-third G. H. A. Clowes memorial award lecture. Cancer Res., 54: 1178-1189, 1994.
5. Dlugosz, A., Cheng, C., Williams, E. K., Dharia, A. G., Denning, M. F., and Yuspa, S. H. Alterations in murine keratinocyte differentiation induced by activated Ha-ras genes are mediated by protein kinase C-α. Cancer Res., 54: 6413-6420, 1994.
6. Housey, G. M., Johnson, M. D., Hsiao, W. L. W., O'Brian, C. A., Murphy, J. P., Kirshmeier, P., and Weinstein, I. B. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell, 52: 343-354, 1988.
7. Persons, D. A., Wilkison, W. O., Bell, R. M., and Finn, O. J. Altered growth regulation and enhanced tumorigenicity of NlH 3T3 fibroblasts transfected with protein kinase C-1 cDNA. Cell, 52: 447-458, 1988.
8. Choi, P. L., Tchou-Wong, K. M., and Weinstein, I. B. Overexpression of protein kinase C in Ht29 colon cancer cells causes growth inhibition and tumor suppression. Mol. Cell. Biol., 10: 4650-4657, 1990.
9. Ways, D. K., Kukoly, C. A., deVente, J., Hooker, J. L., Bryant, W. O., Posekany, K. J., Fletcher, D. J., Cook, P. P., and Parker, P. P. MCF-7 breast cancer cells transfected with with PKC-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest., 95: 1906-1915, 1995.
10. Basu, A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol. & Ther., 59: 257-280, 1993.
11. Aflalo, E., Wolfson, M., Ofir, R., and Weinstein, Y. Elevated activities of protein kinase C and tyrosine kinase correlate to leukemic cell aggressiveness. Int. J. Cancer, 50: 136-141, 1992.
12. Alvaro, V., Touraine, P., Raisman Vozari, R., Bai-Grenier, F., Birman, P., and Joubert, D. Protein kinase C activity and expression in normal and adenomatous human pituitaries. Int. J. Cancer, 50: 724-730, 1992.
13. Benzil, D. B., Finkelstein, S. D., Epstein, M. H., and Finch, P. W. Expression pattern of α-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res, 52: 2951-2956, 1992.
14. O'Brian, C., Vogel, V. G., Singletary, S. E., and Ward, N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue Cancer Res., 49: 3215-3217, 1989.
15. Weinstein, B. I. Cancer prevention recent progress and future opportunities. Cancer Res., 51 (Suppl.): 5080s-5085s, 1991.
16. Gescher, A., and Dale, I. L. Protein kinase C - a novel target for rational anti-cancer drug design? Anti-Cancer Drag Des., 4: 93-105, 1995.
17. O'Brian, C. A., and Kuo, J. F. Protein kinase C inhibitors. In: J. F. Kuo (ed.), Protein Kinase C, pp. 96-120. Oxford, United Kingdom: Oxford University Press, 1994.
18. Boyd, M. The future of new drug development. In: J. E. Neiderhuber (ed.), Current Therapy in Oncology, pp. 11-22. Philadelphia: B. C. Decker, Inc., 1993.
19. Mirabelli, C. K. and Crooke, S. T. Antisense oligonucleotides in the context of modern molecular drug discovery and development. In: S. T. Crooke and B. LeBleu (eds.), Antisense Research and Applications, pp. 7-35 Boca Raton, FL: CRC Press, Inc., 1993.
20. Dolnick, B. J. Antisense agents in cancer research and therapeutics. Cancer Invest., 9: 185-194, 1991.
21. Stein, C. A., and Cheng, Y-C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (Washington DC), 267: 1004-1012, 1993.
22. Wagner, R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.), 372: 333-335, 1994.
23. Crooke, S. T. Therapeutic Applications of Oligonucleotides, p. 11-38. Austin, TX: R. G. Landes Co., 1995.
24. Calabretta, B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res., 57: 4505-4510, 1991.
25. Tseng, B. Y., and Brown, K. D. Antisense oligonucleotide technology in the development of cancer therapeutics. Cancer Gene Ther., 1: 65-71, 1994.
26. Dean, N. M., McKay, R., Condon, T. P., and Bennett, C. F. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem., 269: 16416-16424, 1994.
27. Dean, N. M., and McKay, R. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 91: 11762-11766, 1994.
28. McKay, R. M., Cummins, L. L., Graham, M. J., Lesnick, E. A., Owens, S. R., Winniman, M., and Dean, N. M. Enhanced activity of an antisense oligonucleotide targeting murine PKC-α by the incorporation of 2′-O-propyl modifications. Nucleic Acids Res., 24: 411-417, 1996.
29. Crooke, R. M., Hoke, G. D., and Shoemaker, J. E. E. In vitro toxicological evaluation of ISIS 1082, a phosphorothioate oligonucleotide inhibitor of herpes simplex virus. Antimicrob. Agents Chemother., 36: 527-532, 1992.
30. Bennett, C. F., Chiang, M-Y., Chan, H., Shoemaker, J. E. E., and Mirabelli, C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides Mol. Pharmacol., 41: 1023-1033, 1992.
31. Meyer, T., Regenass, U., Fabbro, D., Alten, E., Rosel, J., Muller, M., Caravatti, G., and Matter, A. A derivative of staurosporin (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer, 43: 851-856, 1989.
32. Stein, C. A., and Krieg, A. M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev., 4: 67-69, 1994.
33. Crooke, R. M. In vitro and in vivo toxicology of first generation analogs. In: S. T. Crooke and B. Lebleu (eds.), Antisense Research and Applications, pp. 471-492. Boca Raton, FL: CRC Press, Inc., 1993.
34. Srinivasan, S. K., and Iversen, P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal., 9: 129-137, 1995.
35. Agrawal, S., Temsamani, J., and Tang, J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice Proc. Natl. Acad. Sci. USA, 88: 7595-7599, 1991.
36. Agrawal, S., Temsamani, J., Galbraith, W., and Tang, J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet., 28: 7-16, 1995.
37. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther., 267: 1181-1190, 1993.
38. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther., 269: 89-94, 1994.
39. 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharmacol. & Ther, 56: 641-646, 1994.
40. Shaw, J-P., Kent, K., Bird, J., Fishback, J., and Froehler, B. Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res., 19: 747-750, 1991.
41. Kitajima, I., Shinohara, T., Bilakovics, J., Brown, D. A., Xiao, X., and Nerenberg, M. Ablation of transplanted HTLV-1 Tax-transformed tumors in mice by antisense inhibition of NF-KB. Science (Washington DC), 258: 1792-1795, 1992.
42. Ratajczak, M. Z., Kant, J. A., Luger, S. M., Hijiya, N., Zhang, J., Zon, G., and Gewirtz, A. M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 89: 11823-11827, 1992.
43. Higgins, K. A., Perez, J. R., Coleman, T. A., Dorshkind, K., McComas, W. A., Sarmiento, M. M., Rosen, C. A., and Narayanan, R. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA, 90: 9901-9905, 1993.
44. Skorski, T., Nieborowska-Skorska, M., Nicolaides, N. C., Szczylik, C., Iversen, P., Iozzo, R. V., Zon, G., and Calabretta, B. Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA, 91: 4504-4508, 1994.
45. Schwab, G., Chavany, C., Duroux, I., Goubin, G., Lebeau, J., Hélène, C., and Saison-Behmoaras, T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA, 97: 10460-10464, 1994.
46. Whitesell, L., Rosolen, A., and Neckers, L. M. In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide Antisense Res. Dev., 1: 343-350, 1991.
47. Bishop, J. M. Molecular themes in oncogenesis. Cell, 64: 235-248, 1991.
48. Hunter, T. Cooperation between oncogenes Cell, 64: 249-270, 1991.
49. Sun, Y., Pommier, Y., and Colburn, N. H. Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage Cancer Res., 52: 1907-1915, 1992.
50. Leszczynski, D., Zhao, Y., Luokkamaki, M., and Foegh, M. L. Apoptosis of vascular smooth muscle cells. Am. J. Pathol., 145: 1265-1270, 1994.